AGREEMENTAgreement • July 3rd, 2008 • Buzz Media, Ltd. • Periodicals: publishing or publishing & printing • Nevada
TIFFANY WALSH, businessperson, having an address for notice and delivery located at c/o 11 Thornhill Drive, Suite 216, Dartmouth, Nova Scotia, Canada, B3B 1R9
STOCK OPTION AGREEMENTStock Option Agreement • October 15th, 2008 • Sinobiopharma, Inc. • Periodicals: publishing or publishing & printing • Nevada
THIS STOCK OPTION AGREEMENT (the “Agreement”) is made and entered into to be effective as of the ___ day of ____________, 20__ (the “Date of Grant”) pursuant to the 2008 Stock Option and Incentive Plan (the “Plan”) of the Company.
SHARE EXCHANGE AGREEMENT Among: SINOBIOPHARMA, INC. And: DONGYING PHARMACEUTICAL CO, LIMITED And: THE SHAREHOLDERS OF DONGYING PHARMACEUTICAL CO, LIMITED Notice to the Shareholder of Dongying Pharmaceutical Co, Limited: The Shareholders of Dongying...Share Exchange Agreement • September 26th, 2008 • Sinobiopharma, Inc. • Periodicals: publishing or publishing & printing • Nevada
SINOBIOPHARMA INC., a corporation organized under the laws of the State of Nevada and having an address for notice and delivery located at 2820 W. Charleston Blvd., Suite 22, Las Vegas, Nevada 89102
EXTENSION AGREEMENTExtension Agreement • September 5th, 2008 • Sinobiopharma, Inc. • Periodicals: publishing or publishing & printing
AND WHEREAS Article 6.2 of the Share Exchange Agreement provides that the latest closing date of the transactions contemplated therein shall occur no later than August 31, 2008, subject to an extension as may be mutually agreed to by the parties for a maximum of 14 days per extension;
Re: Subscription AgreementSinobiopharma, Inc. • January 15th, 2010 • Pharmaceutical preparations • New York
This agreement sets forth the terms on which the undersigned (the “Subscriber”) agrees to purchase shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”) of Sinobiopharma, Inc., a Nevada corporation, at a purchase price per Share of $0.10 (the “Purchase Price per Share”).
AgreementAgreement • August 10th, 2010 • Sinobiopharma, Inc. • Pharmaceutical preparations
DongYing has obtained the approval of clinical trial of Eplerenone, and wants to manufacture Eplerenone in a production base which fulfills all the national requirements for medicine production. LianHuan has such production base and wants to co-develop Eplerenone with DongYing in order to be the first one in China to obtain the New Drug Certificate.
SINOBIOPHARMA, INC. Nantong City, Jiangsu Province China 226009 Tel: (86) 51-385328336Sinobiopharma, Inc. • October 15th, 2008 • Periodicals: publishing or publishing & printing • Nevada
This correspondence will specify the consulting arrangement (the “Consulting Agreement”) between the Company and Michael Tan.
Purchase AgreementPurchase Agreement • December 23rd, 2009 • Sinobiopharma, Inc. • Pharmaceutical preparations
This Purchase Agreement (the “Agreement”) is made effective as of December 18, 2009 by and between DongYing (Jiangsu) Pharmaceutical Limited Company, the 100% owned subsidiary of Sinobiopharma, Inc. (“DongYing”), located at No. 2 Zhongtian Road, Nantong, Jiangsu, 226009, P. R. China and Meisu Jining Secience and Technology (Nanjing) Limited Company (“ Meisu Jining”), located at Hubing Xincun, Jiangning Economic and Technology Development District, Nanjing, Jiangsu, 210000, P. R. China, to transfer the right of the Approval Certificate of Clinical Trial of Eplerenone Tablets (the “Certificate”) owned by Meisu Jining to DongYing.
Purchase AgreementPurchase Agreement • December 23rd, 2009 • Sinobiopharma, Inc. • Pharmaceutical preparations
This Purchase Agreement (the “Agreement”) is made effective as of December 18, 2009 by and between DongYing (Jiangsu) Pharmaceutical Limited Company, the 100% owned subsidiary of Sinobiopharma, Inc. (“DongYing”), located at No. 2 Zhongtian Road, Nantong, Jiangsu, 226009, P. R. China and Meisu Jining Secience and Technology (Nanjing) Limited Company (“ Meisu Jining”), located at Hubing Xincun, Jiangning Economic and Technology Development District, Nanjing, Jiangsu, 210000, P. R. China, to transfer the right of the Approval Certificate of Clinical Trial of Eplerenone Capsules (the “Certificate”) owned by Meisu Jining to DongYing.
MAXIMUM AMOUNT LOAN AGREEMENT Bank of Communications Printed in Sep. 2007Loan Agreement • September 15th, 2009 • Sinobiopharma, Inc. • Pharmaceutical preparations
Important notice Please be advised to read carefully of this agreement, especially for the Clause that marked as **. Should the borrower have any question, please contact with lender for more information as soon as possible.
Patent Transfer AgreementPatent Transfer Agreement • December 29th, 2009 • Sinobiopharma, Inc. • Pharmaceutical preparations
-- Whereas, Dr. Lequn Huang and Lei Wang (jointly, the ”Transferors”, and individually, a “Transferor”), own the patent of "Composition for Lyophilized Powder of Atracurium", patent number 200710127756.2, publication number 101084896A, notification number i100531734C, with an application date of June 26th, 2007, authorization date of August 26th, 2009, publication date of December 12th, 2007, and the patent term of 20 years (expiration date is June 25th, 2027) (the “Patent”).
DONGYING PHARMACEUTICAL CO, LIMITED c/o 1225 Prince’s Building Hong KongSinobiopharma, Inc. • September 26th, 2008 • Periodicals: publishing or publishing & printing • British Columbia
Subject to and in accordance with the terms and conditions contained herein, this binding amended letter agreement (the “Agreement”) will set forth the basic understanding, terms and conditions relating to the cancellation of 60,100,500 of the 62,500,500 shares of common stock of the Company registered in the name of Jianguo Wang upon completion of the share exchange agreement between the Company, Dongying BVI and all the shareholders of Dongying BVI (the “Share Exchange Agreement”), whereby the Company will acquire 100% of the issued and outstanding shares of Dongying BVI. Such cancellation by Jianguo Wang is to: (i) encourage the shareholders of Dongying BVI to enter into the Share Exchange Agreement; (ii) allow Dr. Le-qun Lee Huang to be the largest shareholder in the Company; and (iii) encourage equity investment into the Company.
MAGAZINE Buzz Media Ltd. (the “Company” or “Buzz”) ARTIST AGREEMENTArtist Agreement • July 27th, 2007 • Buzz Media, Ltd.
AGREEMENT AND PLAN OF MERGER between SINOBIOPHARMA, INC. SINOBP, INC., and SINOBP1, INC. Dated as of October 25, 2011Agreement and Plan of Merger • November 21st, 2011 • Sinobiopharma, Inc. • Pharmaceutical preparations • Nevada
AGREEMENT AND PLAN OF MERGER, dated as of October 25, 2011, between Sinobiopharma, Inc., a Nevada corporation ("SNBP"), and Sinobp, Inc., a Nevada corporation ("Parent"), and Sinobp1, Inc., a Nevada corporation ("MergerSub"). SNBP and MergerSub are hereinafter collectively referred to as the "Constituent Corporations."
ADCORP BUSINESS CENTRE LIMITEDBuzz Media, Ltd. • July 27th, 2007
The above parties enter into an agreement for the rental of office space on the premises of Adcorp Business Centre Limited, at 11 Thornhill Drive, Dartmouth, NS.
MAXIMUM MORTGAGE CONTRACT Community BankMaximum mortgage contract • September 15th, 2009 • Sinobiopharma, Inc. • Pharmaceutical preparations
IMPROTANT NOTICE Please the mortgager read this contract seriously, especially those articles with mark ▲▲. Please request the mortgagee to give a full explanation if the mortgager has any doubtful point.
SHARE PURCHASE AGREEMENTShare Purchase Agreement • August 22nd, 2008 • Sinobiopharma, Inc. • Periodicals: publishing or publishing & printing • British Columbia
SINOBIOPHARMA, INC., a company incorporated under the laws of the State of Nevada, having an address for notice and deliver at 2820 West Charleston Boulevard, Suite 22, Las Vegas, Nevada, 89102
Purchase AgreementPurchase Agreement • December 23rd, 2009 • Sinobiopharma, Inc. • Pharmaceutical preparations
This Purchase Agreement (the “Agreement”) is made effective as of December 18, 2009 by and between DongYing (Jiangsu) Pharmaceutical Limited Company, the 100% owned subsidiary of Sinobiopharma, Inc. (“DongYing”), located at No. 2 Zhongtian Road, Nantong, Jiangsu, 226009, P. R. China and Meisu Jining Secience and Technology (Nanjing) Limited Company (“ Meisu Jining”), located at Hubing Xincun, Jiangning Economic and Technology Development District, Nanjing, Jiangsu, 210000, P. R. China, to transfer the right of the Approval Certificate of Eplerenone Drug (the “Certificate”) owned by Meisu Jining to DongYing.
SHARE PURCHASE AGREEMENTShare Purchase Agreement • July 27th, 2007 • Buzz Media, Ltd.
THER AGREEMENT is made as of November 8, 2006 (the “Effective Date”) between Tiffany Walsh (“Ms. Walsh”) and BUZZ MEDIA, Ltd., a Nevada Corporation (“BUZZ MEDIA NEVADA”).
DONGYING PHARMACEUTICAL CO, LIMITED c/o 1225 Prince’s Building Hong KongSinobiopharma, Inc. • August 22nd, 2008 • Periodicals: publishing or publishing & printing • British Columbia
Subject to and in accordance with the terms and conditions contained herein, this binding letter agreement (the “Agreement”) will set forth the basic understanding, terms and conditions relating to the cancellation of 59,000,500 of the 62,500,500 shares of common stock of the Company registered in the name of Jianguo Wang upon completion of the share exchange agreement between the Company, Dongying BVI and all the shareholders of Dongying BVI (the “Share Exchange Agreement”), whereby the Company will acquire 100% of the issued and outstanding shares of Dongying BVI. Such cancellation by Jianguo Wang is to: (i) encourage the shareholders of Dongying BVI to enter into the Share Exchange Agreement; (ii) allow Dr. Le-qun Lee Huang to be the largest shareholder in the Company; and (iii) encourage equity investment into the Company.
